文献速递细菌感染、耐药与抗菌药物

达托霉素联合达巴万星或利奈唑胺及达巴万星联合利奈唑胺对MRSA的体外活性

In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains.
PubMed 文献 · J Antimicrob Chemother · 2016-09-28

本研究评估达托霉素联合达巴万星或利奈唑胺、以及达巴万星联合利奈唑胺对30株临床MRSA分离株的体外抗菌活性。采用微量肉汤稀释法和棋盘微量肉汤法测定MIC及联合效应。所有菌株对三种抗生素敏感,达托霉素联合达巴万星或利奈唑胺的协同率均为67%,达巴万星联合利奈唑胺的协同率为60%,提示这些联合方案体外对MRSA感染可能有效。

要点

  • 30株临床MRSA对达托霉素、达巴万星和利奈唑胺均100%敏感。
  • 达托霉素联合达巴万星或利奈唑胺的体外协同率均为67%。
  • 达巴万星联合利奈唑胺的体外协同率为60%。

核心结论

  • 这些新型抗菌药物的体外联合方案对MRSA感染的治疗可能有效。

研究设计与样本

  • 采用微量肉汤稀释法测定30株临床MRSA对达托霉素、达巴万星和利奈唑胺的MIC,并用棋盘微量肉汤法评估联合体外活性。

主要发现

  • 所有30株(100%)MRSA对达托霉素、达巴万星和利奈唑胺均敏感。
  • 达托霉素的MIC50、MIC90和MIC范围分别为1、1和0.5-1 mg/L。
  • 达巴万星的MIC50、MIC90和MIC范围分别为0.12、0.12和0.03-0.12 mg/L。
  • 利奈唑胺的MIC50、MIC90和MIC范围分别为1、2和1-2 mg/L。
  • 达托霉素联合达巴万星或利奈唑胺的协同率均为67%,达巴万星联合利奈唑胺的协同率为60%。

关键数值与推荐

  • 达托霉素和利奈唑胺的MIC按CLSI推荐判读,达巴万星的MIC按FDA推荐判读。
  • 联合协同效应采用棋盘微量肉汤法评估。

临床怎么用

  • 对于MRSA感染,可考虑达托霉素联合达巴万星或利奈唑胺,或达巴万星联合利奈唑胺作为潜在联合治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Combination therapies have a distinct advantage over monotherapies in terms of their broad spectrum, synergistic effect and prevention of the emergence of drug resistance. In the present study, the in vitro antibacterial activity of daptomycin combinations with linezolid and dalbavancin, and dalbavancin with linezolid were evaluated against 30 clinical MRSA strains. METHODS: The MICs of all antibiotics were determined using microbroth dilution as described by the CLSI. The in vitro activities of antibiotics in combination were assessed by using a microbroth 'chequerboard' assay. The MIC values of all antibiotics determined were evaluated in accordance with the recommendations of the CLSI for daptomycin and linezolid, and the FDA for dalbavancin. RESULTS: All strains (100%) were found to be susceptible to daptomycin, dalbavancin and linezolid. The MIC50, MIC90 and MICrange values of these antibiotics were determined to be 1, 1 and 0.5-1 mg/L, 0.12, 0.12 and 0.03-0.12 mg/L, and 1, 2 and 1-2 mg/L, respectively. The rates of synergistic effects were 67% for daptomycin combined with dalbavancin and with linezolid, and 60% for dalbavancin combined with linezolid. CONCLUSIONS: The results of this study show that in vitro combinations of these new antimicrobials will be effective in the therapy of MRSA infections.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Aktas G, Derbentli S. In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains. J Antimicrob Chemother. 2016. PMID: 28073963. doi:10.1093/jac/dkw416

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。